← All trials
NCT05926466
Phase 2Interventional
Includes controlled clinical studies conducted to evaluate the effectiveness of the drug for a particular indication or indications in participants with the disease or condition under study and to determine the common short-term side effects and risks.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Sep 21, 2023
- Primary completion
- Aug 31, 2024
- Completion date
- Aug 31, 2024
- First posted
- Jul 3, 2023
- Last posted
- Dec 22, 2023
- Enrollment
- 90
- Arms / groups
- 4 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Ludwig Maximilians UniversityLead sponsor
- University of LondonCollaborator
- Radboud UniversityCollaborator
- University of California, San FranciscoCollaborator
- Ludwig Maximilians UniversitySponsor investigator
- Ludwig Maximilians UniversityStudy director
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.